Drug-resistance mechanisms and tuberculosis drugs.
Claudio U Köser, Babak Javid, Kathleen Liddell, Matthew J Ellington, Silke Feuerriegel, Stefan Niemann, Nicholas M Brown, William J Burman, Ibrahim Abubakar, Nazir A Ismail, David Moore, Sharon J Peacock, M Estée Török
Author Information
- Claudio U Köser: Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 0QW, UK. Electronic address: cuk21@cam.ac.uk.
- Babak Javid: Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 0QW, UK; School of Medicine, Tsinghua University, Beijing, China.
- Kathleen Liddell: Faculty of Law, University of Cambridge, Cambridge, UK.
- Matthew J Ellington: Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, UK.
- Silke Feuerriegel: Molecular Mycobacteriology, Research Center Borstel, Borstel, Germany; German Centre for Infection Research, Borstel, Germany.
- Stefan Niemann: Molecular Mycobacteriology, Research Center Borstel, Borstel, Germany.
- Nicholas M Brown: Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, UK.
- William J Burman: Denver Public Health, Denver, USA.
- Ibrahim Abubakar: Tuberculosis Section, Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK; Research Department of Infection and Population Health, University College London, London, UK.
- Nazir A Ismail: Centre for Tuberculosis, National Institute for Communicable Diseases, Johannesburg, South Africa.
- David Moore: TB Centre, London School of Hygiene and Tropical Medicine, London, UK; Laboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Sharon J Peacock: Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 0QW, UK; Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
- M Estée Török: Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 0QW, UK; Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
No abstract text available.
- N Engl J Med. 2014 Dec 18;371(25):2435-6
[PMID: 25517715]
- Nature. 2014 Sep 11;513(7517):143
[PMID: 25209761]
- Eur J Hum Genet. 2013 Jun;21(6):585-8
[PMID: 23150081]
- Science. 2005 Jan 14;307(5707):223-7
[PMID: 15591164]
- J Antimicrob Chemother. 2005 Jun;55(6):817-20
[PMID: 15845781]
- J Infect Dis. 2006 Sep 15;194 Suppl 1:S51-8
[PMID: 16921473]
- J Med Chem. 2009 Oct 8;52(19):5789-92
[PMID: 19736929]
- Antimicrob Agents Chemother. 2010 Mar;54(3):1022-8
[PMID: 20038615]
- Science. 2011 Sep 16;333(6049):1630-2
[PMID: 21835980]
- Antimicrob Agents Chemother. 2011 Dec;55(12):5718-22
[PMID: 21930879]
- Antimicrob Agents Chemother. 2012 Dec;56(12):6080-7
[PMID: 23006760]
- Lancet Infect Dis. 2013 May;13(5):449-58
[PMID: 23531393]
- Nat Biotechnol. 2013 Aug;31(8):704-10
[PMID: 23929344]
- N Engl J Med. 2013 Aug 29;369(9):869-75
[PMID: 23841703]
- Nature. 2013 Oct 10;502(7470):S7
[PMID: 24108080]
- Lancet Infect Dis. 2014 Apr;14(4):327-40
[PMID: 24670627]
- Antimicrob Agents Chemother. 2014 May;58(5):2979-81
[PMID: 24590481]
- PLoS One. 2014;9(7):e102135
[PMID: 25010492]
- Eur Respir J. 2015 Feb;45(2):554-7
[PMID: 25359333]
- /Wellcome Trust
- 098600/Wellcome Trust
- HICF-T5-342/Department of Health
Antitubercular Agents
Diarylquinolines
Drug Approval
Humans
Mutation
Nitroimidazoles
Oxazoles
Tuberculosis, Multidrug-Resistant
Antitubercular Agents
Diarylquinolines
Nitroimidazoles
OPC-67683
Oxazoles
bedaquiline
